ranibizumab intravitreal injection — Competitive Intelligence Brief

ranibizumab intravitreal injection (ranibizumab intravitreal injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: anti-VEGF agent. Area: Ophthalmology.

phase 3 anti-VEGF agent VEGF-A Ophthalmology Small molecule

Target snapshot

ranibizumab intravitreal injection (ranibizumab intravitreal injection) — Hawaii Pacific Health. Ranibizumab works by binding to vascular endothelial growth factor A (VEGF-A), preventing its interaction with its receptor and thereby inhibiting angiogenesis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ranibizumab intravitreal injection TARGET	ranibizumab intravitreal injection	Hawaii Pacific Health	phase 3	anti-VEGF agent	VEGF-A
Ketorolac + Ranibizumab	Ketorolac + Ranibizumab	Università degli Studi di Brescia	marketed	NSAID + anti-VEGF monoclonal antibody fragment	COX enzymes (ketorolac); VEGF-A (ranibizumab)
Intravitreal Aflibercept Injection	Intravitreal Aflibercept Injection	Ophthalmic Consultants of Boston	marketed	VEGF inhibitor / Soluble decoy receptor	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
Anti-VEGF drug	Anti-VEGF drug	Xiaodong Sun	marketed	Anti-VEGF	VEGF-A
intravitreal injection with ranibizumab	intravitreal injection with ranibizumab	University Hospital Muenster	marketed	VEGF inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)
Aflibercept Intravitreous Injection	Aflibercept Intravitreous Injection	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	marketed	VEGF inhibitor / Soluble decoy receptor	VEGF-A, VEGF-B, PlGF (placental growth factor)
Ranibizumab and Aflibercept	Ranibizumab and Aflibercept	Instituto de Olhos de Goiania	marketed	Anti-VEGF agent	VEGF-A (vascular endothelial growth factor-A)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (anti-VEGF agent class)

1. Hawaii Pacific Health · 1 drug in this class
2. Jaeb Center for Health Research · 1 drug in this class
3. Moorfields Eye Hospital NHS Foundation Trust · 1 drug in this class
4. Novartis · 1 drug in this class
5. ONL Therapeutics · 1 drug in this class